MEDXF News and Press, Medexus Pharmaceuticals Inc From 06/01/21

TORONTO and CHICAGO and MONTREAL, June 01, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) ( TSXV: MDP , OTCQX: MEDXF ), today announced that management will present at the LD Micro Invitation...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO and CHICAGO and MONTREAL, May 27, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSXV:MDP) (OTCQX: MEDXF) (Frankfur...

May 19 - 20, 2021 Presentation times and weblinks released for over 60 presenting companies NEW YORK, NY / ACCESSWIRE / May 18, 2021 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day spring Microcap Virtual Conference taking place Wedne...

Medexus Pharmaceuticals Inc. (TSX.V: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is a leading innovative and rare disease company with a strong North American commercial platform. From a foundation of proven best in class products, Medexus is building a highly differentiated company with a portfol...

TORONTO, CHICAGO and MONTREAL, May 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Sidoti & Company Virtual Mi...

TORONTO and CHICAGO and MONTREAL, April 12, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731), today announced that Ken d’Entremont, CEO, and Roland Boivin, CFO, will ...

TORONTO, CHICAGO and MONTREAL, March 31, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) is pleased to report that the Company’s non-executive directors were permitt...

TORONTO, CHICAGO and MONTREAL, March 08, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that Ken d’Entremont, Chief Executive Officer, and Rolan...

Medexus Pharmaceuticals (MEDXF): FQ3 Adj. EBITDA of C$5.1M.Revenue of C$31.5M (+94.4% Y/Y)Press Release For further details see: Medexus Pharmaceuticals reports FQ3 results

TORONTO, CHICAGO and MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “ Company ” or “Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced its financial and operating results for the three and nine mont...